Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Toll-like Receptor 5 Agonism Protects Mice from Radiation Pneumonitis and Pulmonary Fibrosis

  • Wang, Zhi-Dong (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine) ;
  • Qiao, Yu-Lei (College of Life Science, Hebei United University) ;
  • Tian, Xi-Feng (College of Life Science, Hebei United University) ;
  • Zhang, Xue-Qing (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine) ;
  • Zhou, Shi-Xiang (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine) ;
  • Liu, Hai-Xiang (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine) ;
  • Chen, Ying (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Radiation pneumonitis and pulmonary fibrosis are the main complications with radiotherapy for thoracic neoplasms, directly limiting the efficient dose in clinical application and currently there are few medicines that effectively function as radioprotectants. However, a TLR5 agonist, CBLB502, was confirmed to have protective efficacy against hematopoietic and gastrointestinal radiation syndromes in mice and primates. This study points to a new direction for protection against thoracic radiation-induced pulmonary syndromes and skin injury by CBLB502. We utilized the TUNEL assay, pathological analysis and immunohistochemistry to obtain evidence thatCBLB502 could alleviate the occurrence of radiation pneumonitis and pulmonary fibrosis as well as radiation-induced skin injury. It may thus play a promising role in facilitating clinical radiotherapy of thoracic neoplasms.

Keywords

References

  1. Atkinson K, Vos B, Kang-Er Z, et al (1995).Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graftversus- host disease and survival after murine haematopoietic stem cell transplantation. Cytokines Mol Ther, 1, 47-55.
  2. Brickey WJ, Neuringer IP, Walton W, et al (2012).MyD88 provides a protective role in long-term radiation-induced lung injury. Int J Radiat Biol, 88, 335-47. https://doi.org/10.3109/09553002.2012.652723
  3. Burdelya LG, Gleiberman AS, Toshkov I, et al (2012). Tolllike receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys, 83, 228-34. https://doi.org/10.1016/j.ijrobp.2011.05.055
  4. Burdelya LG, Krivokrysenko VI, Tallant TC, et al (2008). An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320, 226-30. https://doi.org/10.1126/science.1154986
  5. Dale DC (2002). Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs, 62, S1-15.
  6. Delanian S, Baillet F, Huart J, et al (1994). Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase (clinical trial). Radiother Oncol, 32, 12-20. https://doi.org/10.1016/0167-8140(94)90444-8
  7. Epperly MW, Sikora CA, DeFilippi SJ, et al (2002).Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res, 157, 568-77. https://doi.org/10.1667/0033-7587(2002)157[0568:MSDSIR]2.0.CO;2
  8. Krivokrysenko V, Shakhov A, Singh V, et al (2012). Identification of G-CSF and IL-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure. J Pharmacol Exp Ther, 343, 497-508. https://doi.org/10.1124/jpet.112.196071
  9. Kuwano K, Hagimoto N, Kawasaki M, et al (1999). Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J ClinInvest, 104, 13-9
  10. Mehta V (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys, 63, 5-24. https://doi.org/10.1016/j.ijrobp.2005.03.047
  11. Tallant T, Deb A, Kar N, et al (2004). Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells. BMCMicrobiol, 4, 33.
  12. Vijay-Kumar M, Aitken JD, Sanders CJ, et al (2008).Flagellin treatment protects against chemicals, bacteria,viruses, and radiation. J Immunol, 180, 8280-5. https://doi.org/10.4049/jimmunol.180.12.8280
  13. Wynn TA (2007). Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest, 117, 524-9. https://doi.org/10.1172/JCI31487
  14. Zhou SX, Li FS, Qiao YL, et al (2012). Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner. Asian Pac J Cancer Prev, 13, 2807-12. https://doi.org/10.7314/APJCP.2012.13.6.2807

Cited by

  1. Peptidoglycans Promotes Human Leukemic THP-1 Cell Apoptosis and Differentiation vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6409
  2. Suggestion for a New Grading Scale for Radiation Induced Pneumonitis Based on Radiological Findings of Computerized Tomography: Correlation with Clinical and Radiotherapeutic Parameters in Lung Cancer Patients vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2717
  3. Trial Watch vol.2, pp.9, 2013, https://doi.org/10.4161/onci.25595
  4. High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer vol.140, pp.4, 2014, https://doi.org/10.1007/s00432-014-1616-4
  5. Evaluation of the Radiation Pneumonia Development Risk in Lung Cancer Cases vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7371
  6. Plant Extracts and Plant-Derived Compounds: Promising Players in Countermeasure Strategy Against Radiological Exposure: A Review vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2405
  7. Strahlenschutz von Normalgewebszellen vol.190, pp.8, 2014, https://doi.org/10.1007/s00066-014-0637-x
  8. Trial Watch: Radioimmunotherapy for oncological indications vol.3, pp.9, 2014, https://doi.org/10.4161/21624011.2014.954929
  9. Establishment of a mouse model of 70% lethal dose by total-body irradiation vol.32, pp.2, 2016, https://doi.org/10.5625/lar.2016.32.2.116
  10. Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades vol.12, pp.1, 2017, https://doi.org/10.1186/s13014-017-0865-1
  11. Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation vol.187, pp.5, 2017, https://doi.org/10.1667/RR14514.1
  12. Toll-like receptor 5 agonist CBLB502 induces radioprotective effects in vitro vol.49, pp.6, 2017, https://doi.org/10.1093/abbs/gmx034
  13. Radioprotective agents for radiation therapy: future trends vol.10, pp.15, 2014, https://doi.org/10.2217/fon.14.175
  14. Repeated injection of KMRC011, a medical countermeasure for radiation, can cause adverse health effects in cynomolgus monkeys pp.0260437X, 2018, https://doi.org/10.1002/jat.3719
  15. Radioprotective Efficiency of Recombinant Flagellin and Interleukin-1 Beta with Combined Administration vol.52, pp.10, 2019, https://doi.org/10.1007/s11094-019-1910-1